Clusterul Regional Inovativ de Imagistică Moleculară și Structurală Nord-Est IMAGO-MOL is partner in the project PRECISEU (PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope), co-funded through Horizon Europe programme.

The project consortium includes 25 partners from 12 European regions of 11 countries (Spain, Germany, Italy, Belgium, the Netherlands, Sweden, Greece, Romania, Bulgaria, Lithuania, and Ukraine), being coordinated by Biocat, BioRegion of Catalonia, Spain.

The general objective of PRECISEU is to increase the efficiency regional innovation ecosystems through strengthened collaboration and shared resources on strategic areas of regional strength and specialisation, enabling the development and implementation of innovative initiatives, and facilitating the digital and sustainable transformation of the healthcare systems.

The project aims to accelerate the adoption of PM at European level, reducing the fragmentation and inequalities across EU and supporting the implementation of deep-tech innovation in diverse ecosystems with different innovation levels, assets, strategies, and policies.

Specific objectives:

  • To interconnect a significant number (12) of European regional ecosystems (from 11 EU MS and 1 associated country), through their Regional Authorities and/or main healthcare innovation stakeholders, connecting regions with different innovation level and strengthening their capacity to innovate in deep-tech to collectively contribute to the New European Innovation Agenda implementation,
  • To develop and implement a methodology to support and complement initiatives on Personalised Medicine, at EU level and beyond, answering to specific calls to action (Triplets of Action) of the EC’s and IC PerMed’s Strategic Agenda of Research and Innovation on Personalised Medicine,
  • To address main obstacles, linked to SRIA’s ToA and knowledge from the participating regions for sustainable and affordable integration of PM strategies into healthcare systems, blueprinting mechanisms, infrastructures, and policy approaches, developing reference frameworks to support integrated large data sets available for secondary data use, adding visibility to ATMP infrastructure in Europe to facilitate the exchange of knowledge and ideas within the EU by connecting stakeholders and current available infrastructures and facilitating translation to the clinic and transfer of practices across regions,
  • To establish innovation alliances across the value chain, with industrial partners and healthcare providers tosupport the access of PM to the market: based on business models, open innovation collaboration models and best practices for harmonization on following testbeds,sandboxes,sustainable models,regulatory issues, market access needs and solutions, new financial approaches, innovation procurement approaches for 5P (or PM). And make it transferable across regions,
  • To empower professionals and policymakers by developing their skills, confidence and effective understanding of health-related data use and ATMPs for PM models, foster a better understanding of deep tech and encourage the adoption of innovative approaches, inspiring and advocating for the broader adoption of the model,
  • To implement an Innovation Support Program with funnelling and monitoring phases, supporting concrete interregional projects to be implemented by consortia with research and innovation (R&I) entities from participating regions, to bring innovations on the use of health data for R&I, to make ATMPs sustainable and affordable and to introduce PM in regional healthcare systems, even in regions with lower innovation performance.

PRECISEU ambitions to contribute to healthcare transformation, overcoming the burdens that lag Personalised Medicine and draw back its successful implementation in health systems across Europe.

PRECISEU also ambitions to improve prevention, diagnostics and treatments, realizing the potential of technologies and the  secondary use of health-related data; to help bring advanced therapy medicinal products (ATMPs) to the patients and the markets, as prioritises the European Medicines Agency (EMA’s) regulatory strategy for 2025 (Goal 1 “Support translation of advanced therapy medicinal products (ATMPs) into patient Treatments).

Implementation period: 01.07.2024 – 30.06.2029
Overall amount of the grant: 22.730.100 euro
Overall amount of IMAGO-MOL budget: 66.250 euro 

Contact person: Carmen Mihai, IMAGO-MOL Cluster Manager, carmen.mihai@imago-mol.ro